Safety of increased radiation doses with hormone therapy for high-risk prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety of dose escalation in hypofractionated radiation therapy combined with hormone therapy for patients with high-risk localized prostate cancer. It aims to determine whether increasing the radiation dose to 70 Gy or more can reduce the risk of biochemical failure while minimizing side effects to surrounding normal tissues. The study utilizes advanced techniques such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) to enhance treatment efficacy. Participants will receive a biodegradable material injection to facilitate the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histopathologically confirmed prostate adenocarcinoma within 6 months of study enrollment
2. Patients with prostate cancer at high risk or above (c T3a-T4 or grade group 4-5 or PSA \> 20 n g/mL) )
3. Patients who have undergone or are scheduled to undergo hormone therapy for high-risk prostate cancer
4. Adults over 20 years of age
5. Whole body performance ECOG 0-1
6. SpaceOAR Patients who consented to the procedure and study

Exclusion Criteria:

1. prostate removal surgery, Patients with a history of lower pelvic surgery including rectal cancer surgery
2. primary cancer Patients with posterior extracapsular extension
3. Medically biodegradable substances such as bleeding predisposition Patients for whom infusion is not appropriate
4. Patients with a history of previous pelvic radiation therapy
5. Patients with lymph node metastasis or distant metastasis

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Won Park, M.D., Ph.D.
• Email: wonro.park@samsung.com
• Phone: +82-2-3410-2616

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Darolutamide with standard or higher-dose targeted prostate radiotherapy plus hormone therapy for men with high-risk localized prostate cancer

  This trial tests whether adding darolutamide and/or using higher-dose targeted prostate radiotherapy together with hormone therapy and pelvic nodal radiotherapy helps men with localized high‑risk prostate cancer stay free of metastatic disease longer.

  Recruiting at 6 sites Phase 3 Unicancer · Brest and 5 other locations · NCT06625970

• Combining advanced treatments for high risk prostate cancer

  This study is testing a new treatment approach for men with high risk prostate cancer to see if combining different therapies can improve their outcomes while causing fewer side effects.

  Recruiting Haaglanden Medical Centre · Leidschendam, South Holland · NCT06204341

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Targeted tumor boost and shortened radiation schedules for prostate cancer

  This trial tests whether giving a higher radiation dose to the tumor inside the prostate (a focal boost) and delivering treatment in 12 instead of 20 sessions helps men with intermediate- or high-risk prostate cancer have fewer relapses and need less hormonal therapy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Aarhus and 2 other locations · NCT07343349

• Radiation therapy options for high-risk prostate cancer

  This trial tests different ways of giving radiation therapy to see which balance best controls the cancer with the fewest side effects in men with high-risk, non-metastatic prostate cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07751159

• Repeated PSMA PET scans to monitor treatment response in clinically significant prostate cancer.

  This project will test whether doing a PSMA PET/CT before treatment and again after treatment (or at early PSA rise) helps track response in people with newly diagnosed clinically significant (Gleason ≥7) prostate cancer.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553780

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.